Granted Patent
B2
US 12,351,614 · App. 17/598,573 · Granted Jul 8, 2025
CLEC9A-based chimeric protein complexes
Inventors:
Nikolai Kley (Waltham, MA); Erik Depla (Zwijnaarde, BE); Lennart Zabeau (Zwijnaarde, BE); Jan Tavernier (Zwijnaarde, BE)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates, in part, to chimeric protein complexes including an anti-Clec9A targeting moiety, a modified Fc domain, and a modified human IFNα and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric protein complexes and their use in the treatment of various diseases.
Claims (9)
1. A chimeric protein complex comprising:
(i) a targeting moiety that specifically binds to C-type lectin domain family 9 member A (Clec9A),
(ii) a modified human IFNα2, and
(iii) a modified Fc domain,
wherein the chimeric protein complex comprises a polypeptide having the amino acid sequence of SEQ ID NO: 2 and further comprises a polypeptide having the amino acid sequence of SEQ ID NO: 7.
2. A method for treating a cancer, comprising administering an effective amount of the chimeric protein complex of claim 1 to a patient in need thereof.
3. A pharmaceutical composition comprising the chimeric protein complex of claim 1 and a pharmaceutically acceptable carrier.
4. A recombinant nucleic acid composition encoding the chimeric protein complex of claim 1 , or constituents thereof.
5. A host cell comprising the nucleic acid of claim 4 .
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2023
From: KLEY, NIKOLAI
To: ORIONIS BIOSCIENCES, INC.
Reel/Frame 064324/0132 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2023
From: DEPLA, ERIK; ZABEAU, LENNART; TAVERNIER, JAN
To: ORIONIS BIOSCIENCES BV
Reel/Frame 064324/0160 →
Continuity (3)
Provisional Application
62906442
· Sep 26, 2019
Provisional Application
62825584
· Mar 28, 2019
References Cited (161)
US 5914254A
· Mascarenhas et al.
· 1999
[cited by applicant]
US 8580266B2
· Sancho-Madrid et al.
· 2013
[cited by applicant]
US 8980267B2
· Grewal et al.
· 2015
[cited by applicant]
US 9139634B2
· Morrison et al.
· 2015
[cited by applicant]
US 9492562B2
· Tavernier et al.
· 2016
[cited by applicant]
US 9534056B2
· Grewal et al.
· 2017
[cited by applicant]
US 9732135B2
· Tavernier et al.
· 2017
[cited by applicant]
US 9878014B2
· Tavernier et al.
· 2018
[cited by applicant]
US 9914759B2
· Tavernier et al.
· 2018
[cited by applicant]
US 9932409B2
· Tavernier et al.
· 2018
[cited by applicant]
US 20110020273A1
· Chang et al.
· 2011
[cited by applicant]
US 20110224407A1
· Langer et al.
· 2011
[cited by applicant]
US 20130183298A1
· Le et al.
· 2013
[cited by applicant]
US 20140271462A1
· Ho et al.
· 2014
[cited by applicant]
US 20150265721A1
· Lahoud et al.
· 2015
[cited by applicant]
US 20160145325A1
· Varheesen et al.
· 2016
[cited by applicant]
US 20180186894A1
· Tavernier et al.
· 2018
[cited by applicant]
US 20180334489A1
· Tavernier et al.
· 2018
[cited by applicant]
US 20190202934A1
· Tavernier et al.
· 2019
[cited by applicant]
RU 2011127226A
· 2013
[cited by applicant]
WO WO9102754A1
· 1991
[cited by applicant]
WO WO03033720A2
· 2003
[cited by applicant]
WO WO2006053883A1
· 2003
[cited by applicant]
WO WO2006115800A2
· 2006
[cited by applicant]
WO WO2008014612A1
· 2008
[cited by applicant]
WO WO2008124086A2
· 2008
[cited by applicant]
WO WO2009003145A1
· 2008
[cited by applicant]
WO WO2009013484A1
· 2009
[cited by applicant]
WO WO2009039409A1
· 2009
[cited by applicant]
WO WO2010036918A2
· 2010
[cited by applicant]
WO WO2010066740A1
· 2010
[cited by applicant]
WO WO2011020783A2
· 2011
[cited by applicant]
WO WO2011029870A1
· 2011
[cited by applicant]
WO WO2012170072A1
· 2012
[cited by applicant]
WO WO2013053008A2
· 2013
[cited by applicant]
WO WO2013059885A2
· 2013
[cited by applicant]
WO WO2013107791A1
· 2013
[cited by applicant]
WO WO2013134138A1
· 2013
[cited by applicant]
WO WO2013163689A1
· 2013
[cited by applicant]
WO WO2015007520A1
· 2015
[cited by applicant]
WO WO2015007536A2
· 2015
[cited by applicant]
WO WO2015007542A1
· 2015
[cited by applicant]
WO WO2015007903A1
· 2015
[cited by applicant]
WO WO2015018528A1
· 2015
[cited by applicant]
WO WO2016187459A1
· 2016
[cited by applicant]
WO WO2017077382A1
· 2017
[cited by applicant]
WO WO2017134301A1
· 2017
[cited by applicant]
WO WO2017134302A2
· 2017
[cited by applicant]
WO WO2017134305A1
· 2017
[cited by applicant]
WO WO2017134306A1
· 2017
[cited by applicant]
WO WO2017153402A1
· 2017
[cited by applicant]
WO WO2017194782A2
· 2017
[cited by applicant]
WO WO2017194783A1
· 2017
[cited by applicant]
WO WO2018077893A1
· 2018
[cited by applicant]
WO WO2018141964A1
· 2018
[cited by applicant]
WO WO2018144999A1
· 2018
[cited by applicant]
WO WO2019032661A1
· 2019
[cited by applicant]
WO WO2019032662A1
· 2019
[cited by applicant]
WO WO2019032663A1
· 2019
[cited by applicant]
WO WO2019148089A1
· 2019
[cited by applicant]
WO WO2019152979A1
· 2019
[cited by applicant]
WO WO2019191519A1
· 2019
[cited by applicant]
WO WO2020033646A1
· 2020
[cited by applicant]
Yan et al. Oncotarget. Jun. 28, 2016;7(26):40437-40450. (Year: 2016)
[cited by examiner]
Zeng et al. J Clin Invest. May 1, 2018;128(5):1971-1984. Epub Apr. 9, 2018 (Year: 2018).
[cited by examiner]
Tullett et al. JCI Insight. May 19, 2016;1(7):e87102. (Year: 2016).
[cited by examiner]
Acres, et al., “Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity,” Cancer Res., vol. 65, No. 20, pp. 9536-9546, 2005.
[cited by applicant]
Baba, et al., “Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-Directed CC Chemokine LARC,” The Journal of Biological Chemistry, vol. 272, No. 23, pp. 14893-14898, 1997.
[cited by applicant]
Barbara, et al., “Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF-α mutants,” EMBO Journal, vol. 13, No. 4, pp. 843-850, 1994.
[cited by applicant]
Bork, et al., “Go hunting in sequence databases but watch out for the traps.” Trends in Genetics, Oct. 1996, vol. 12, No. 10, pp. 425-427.
[cited by applicant]
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10, pp. 398-400, 2000.
[cited by applicant]
Boschert, et al., “Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2,” Cellular Signalling 22 (7):10…
[cited by applicant]
Bremer, et al., “Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists,” Cancer Res. 68: 597-604, 2008.
[cited by applicant]
Brown, et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” J. Immunol., May 1, 1996, vol. 156, No. 9, pp. 3285…
[cited by applicant]
Camacho, et al., “Structure of an Interleukin-1β Mutant With Reduced Bioactivity Shows Multiple Subtle Changes in Conformation That Affect Protein-Protein Recognition,” Biochemistry, vol. 32, No. 34, pp. 8749-8757, 1993.
[cited by applicant]
Coulstock, et al., “Liver-Targeting of Interferon-Alpha with Tissue Specific Domain Antibodies,” PLOS ONE, vol. 8, No. 2, pp. 1-11, 2013.
[cited by applicant]
De Bruyn, et al., “Antibody-Based Fusion Proteins to Target Death Receptors in Cancer,” Cancer Letters, vol. 332, pp. 175-183, 2013.
[cited by applicant]
Deffar, et al., “Nanobodies—The New Concept in Antibody Engineering,” African Journal of Biotechnology, vol. 8, No. 12, pp. 2645-2652, 2009.
[cited by applicant]
Dijkmans, et al., “Murine Interferon-γ Interleukin-1 Fusion Proteins Used as Antigens for the Generation of Hybridomas Producing Monoclonal Anti-Interleukin-1 Antibodies,” Cytokine, vol. 3, No. 2, pp. 134-140, 1991.
[cited by applicant]
Dimitrov, “Engineered CH2 Domains (Nanoantibodies),” mAbs, Landes Bioscience, vol. 1, No. 1, pp. 26-28, 2009.
[cited by applicant]
Edelman, et al., “The Covalent Structure of an Entire Tg Immunoglobulin Molecule*,” Biochemistry, 1969; vol. 63, No. 1, 78-85.
[cited by applicant]
Frey, et al., “Antibody-Based Targeting of Interferon-Alpha to the Tumor Neovasculature: A Critical Evaluation,” ntegrative Biology, vol. 3, pp. 468-478, 2011.
[cited by applicant]
Garcin, et al., “High Efficiency cell-specific targeting of cytokine activity,” Nature Communications, vol. 5, No. 8, 9 pages, 2014.
[cited by applicant]
Garlanda, et al., “The Interleukin-1 Family: Back to the Future,” Immunity, 39 (6): pp. 1003-1018, Dec. 12, 2013.
[cited by applicant]
Holler, et al., “Two Adjacent Trimeric Fas Ligands are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex,” Molecular and Cellular Biology, vol. 23, No. 4, pp. 1428-1440, 2003.
[cited by applicant]
Huang, et al., “A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-[alpha] Fusion Protein Induces HER2/Neu Signaling and Facilitates Repair of Injured Epithelia,” The Journal of Pharmacology and Experimental Therap…
[cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP2017/052544, dated Jun. 6, 2017, 16 pages.
[cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/EP2018/54742, dated Dec. 6, 2018, 20 pages.
[cited by applicant]
Idoyaga, et al., “Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A,” PNAS, vol. 108, No. 6, pp. 2384-2389, Jan. 24, 20…
[cited by applicant]
Kircheis, et al., “Biological activity of mutants of human tumour necrosis factor-alpha,” Immunology, pp. 433-438, Jul. 1, 1992.
[cited by applicant]
Krippner-Heidenreich, et al., “Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity,” The Journal of Immunology, vol. 180, pp. 8176-8183, 2008.
[cited by applicant]
Lahoud, et al., “Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype,” The Journal of Immunology, vol. 187, No. 2, pp. 842-850, Jul. 15, …
[cited by applicant]
Loetscher, et al., “Human Tumor Necrosis Factor α (TNFα) Mutants with Exclusive Specificity for 55-kDA or 75-kDa TNF Receptors,” Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, …
[cited by applicant]
Masci, et al., “New and Modified Interferon alfas: Preclinical and Clinical Data,” Current Oncology Reports, vol. 5, pp. 108-113, 2003.
[cited by applicant]
Merchant, et al., “An efficient route to human bispecific IgG.,” Nature Biotechnology, 1998, vol. 16, pp. 677-681. Abstract.
[cited by applicant]
Minn, “Interferons and the Immunogenic Effects of Cancer Therapy,” Trends In Immunology, vol. 36, No. 11, pp. 725-737, Nov. 1, 2015.
[cited by applicant]
Ngo, et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction,” Edited by: Mertz et al., (Birkhauser, Boston), pp. 491-495…
[cited by applicant]
Pan, et al., “Mutation of the IFNAR-1 Receptor Binding Site of Human IFN-α2 Generates Type I IFN Competitive Antagonists,” Biochemistry, vol. 47, pp. 12018-12027, 2008.
[cited by applicant]
Patris, et al., “Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination,” Talanta, 2014, vol. 130, pp. 164-170, 2014.
[cited by applicant]
Penafuerte, et al., “The Human Ortholog of Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 fusion Protein Induces Potent Ex Vivo Natural Killer Cell Activation and Maturation,” Cancer Res, vol. 69, No…
[cited by applicant]
Picco, et al., “Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas,” European Journal of Immunology, vol. 44, No. 7, pp. 1947-1955, Apr. 17, 2014.
[cited by applicant]
Piehler, et al., New Structural and Functional Aspects of the Type I Interferon-Receptor Interaction Revealed by Comprehensive Mutational Analysis of the Binding Interface* JBC, 2000, vol. 275, No. 51, pp. 40425-40433.
[cited by applicant]
Puskas, et al., “Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases,” Immunology, vol. 133, No. 2, pp. 206-220, Jun. 23, 2011.
[cited by applicant]
Rafei, et al., “A MCP1 Fusokine with CCR2-Specific Tumoricidal Activity,” Molecular Cancer, vol. 10, No. 121, pp. 1-11, 2011.
[cited by applicant]
Rafei, et al., “An Engineered GM-CSF-CCL2 Fusokine Is a Potent Inhibitor of CCR2-Driven Inflammation as Demonstrated in a Murine Model of Inflammatory Arthritis,” The Journal of Immunology, vol. 183, pp. 1759-1766, 2009.
[cited by applicant]
Ridgway, et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Engineering, 1996, vol. 9, No. 7, pp. 617-621.
[cited by applicant]
Roisman, et al., “Structure of the Interferon-Receptor Complex Determined by Distant Constraints from Double Mutant Cycles and Flexible Docking,” PNAS, vol. 98, No. 23, pp. 13231-13236, 2001.
[cited by applicant]
Rovero, et al., “Insertion of the DNA for the 163-171 Peptide of IL 1 II Enables a DNA Vaccine Encoding p185
[cited by applicant]
Rudikoff, et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, Mar. 1982, vol. 79, pp. 1979-1983.
[cited by applicant]
Sancho, et al., “Identification of a dendritic cell receptor that couples sensing of necrosis to immunity,” Nature, Nature Publishing Group, United Kingdom, vol. 453, No. 7240, pp. 899-903, Apr. 16, 2009.
[cited by applicant]
Schutyser, et al., “The CC Chemokine CCL20 and its Receptor CCR6,” Cytokine & Growth Factor Reviews, vol. 14, pp. 409-426, 2003.
[cited by applicant]
Vaneycken, et al., “Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer”, The ASEB Journal, vol. 25, pp. 2433-2446, 2011.
[cited by applicant]
Vajdos, et al., “Comprehensive Functional Maps of the Antigen binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis”, JMB, 2002, vol. 320, pp. 415-428.
[cited by applicant]
Weber, et al., “Single Amino Acid Changes that Render Human IFN-α2 Biologically Active on Mouse Cells,” The EMBO Journal, vol. 6, No. 3, pp. 591-598, 1987.
[cited by applicant]
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517, 1990.
[cited by applicant]
Wesolowski, et al., “Single Domain Antibodies: Promising Experimental and Therapeutic Tools in Infection and Immunity,” Med. Microbiol. Immunol., vol. 198, pp. 157-174, 2009.
[cited by applicant]
Zitvogel, et al., “Type I interferons in anticancer immunity,” The Journal of Immunology, vol. 15, No. 7, pp. 405-141, Jun. 1, 2015.
[cited by applicant]
International Search Report & Written Opinion, PCT Application No. PCT/US2020/025423, dated Jul. 22, 2020, 13 pages.
[cited by applicant]
Paul, “Targeting of alpha interferon activity: from the evidence concept to biological activity,” Thesis, Université Montpellier, Apr. 20, 2017, 196 pages.
[cited by applicant]